Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anat Peck is active.

Publication


Featured researches published by Anat Peck.


International Journal of Antimicrobial Agents | 2012

Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients

Ron Ram; Laura Farbman; Leonard Leibovici; Pia Raanani; Moshe Yeshurun; Liat Vidal; Anat Gafter-Gvili; Anat Peck; Ofer Shpilberg; Mical Paul

Surveys of bacterial infections among neutropenic cancer patients frequently report pooled antibiotic susceptibility data. Management guidelines address initial antibiotic regimens for febrile neutropenia. In this study, rates of bacterial infection and antibiotic susceptibilities among initial and subsequent or breakthrough episodes of fever were analysed. Prospective surveillance of fever of unknown origin (FUO), clinically documented infection and microbiologically documented infection (MDI) was conducted in the haemato-oncology and haematopoietic stem cell transplantation wards in a single cancer centre in Israel. Subsequent infections were defined as those developing during or after broad-spectrum antibiotic treatment. A total of 567 febrile episodes were documented among 271 patients. Bacterial MDIs were documented in 104/162 (64%) initial febrile episodes and 75/405 (19%) subsequent episodes and Gram-negative bacteria predominated (64% and 71%, respectively). Escherichia coli was the most common species isolated. Higher antibiotic susceptibilities were observed for initial compared with subsequent MDIs for Gram-negative bacteria [ceftazidime 80% vs. 45%, piperacillin/tazobactam (TZP) 86% vs. 40% and meropenem 95% vs.76%] and Gram-positive bacteria. TZP monotherapy was the most commonly used antibiotic and its susceptibility decreased to 22.2% following its use. Appropriate empirical antibiotic treatment was administered in 71/97 (73%) initial and 40/74 (54%) subsequent episodes (P=0.009) and was significantly associated with mortality (adjusted odds ratio=0.4, 95% confidence interval 0.18-0.87). We conclude that previous antibiotic exposure significantly impacts antibiotic susceptibility and that pooled reporting of all infections can be misleading. Treatment guidelines should address the antibiotic treatment of breakthrough fever.


Biology of Blood and Marrow Transplantation | 2015

Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study

Moshe Yeshurun; Ofer Shpilberg; Corina Herscovici; Liat Shargian; Juliet Dreyer; Anat Peck; Moshe Israeli; Maly Levy-Assaraf; Tsipora Gruenewald; Raphael Mechoulam; Pia Raanani; Ron Ram

Graft-versus-host-disease (GVHD) is a major obstacle to successful allogeneic hematopoietic cell transplantation (alloHCT). Cannabidiol (CBD), a nonpsychotropic ingredient of Cannabis sativa, possesses potent anti-inflammatory and immunosuppressive properties. We hypothesized that CBD may decrease GVHD incidence and severity after alloHCT. We conducted a phase II study. GVHD prophylaxis consisted of cyclosporine and a short course of methotrexate. Patients transplanted from an unrelated donor were given low-dose anti-T cell globulin. CBD 300 mg/day was given orally starting 7 days before transplantation until day 30. Forty-eight consecutive adult patients undergoing alloHCT were enrolled. Thirty-eight patients (79%) had acute leukemia or myelodysplastic syndrome and 35 patients (73%) were given myeloablative conditioning. The donor was either an HLA-identical sibling (n = 28), a 10/10 matched unrelated donor (n = 16), or a 1-antigen-mismatched unrelated donor (n = 4). The median follow-up was 16 months (range, 7 to 23). No grades 3 to 4 toxicities were attributed to CBD. None of the patients developed acute GVHD while consuming CBD. In an intention-to-treat analysis, we found that the cumulative incidence rates of grades II to IV and grades III to IV acute GVHD by day 100 were 12.1% and 5%, respectively. Compared with 101 historical control subjects given standard GVHD prophylaxis, the hazard ratio of developing grades II to IV acute GVHD among subjects treated with CBD plus standard GVHD prophylaxis was .3 (P = .0002). Rates of nonrelapse mortality at 100 days and at 1 year after transplantation were 8.6% and 13.4%, respectively. Among patients surviving more than 100 days, the cumulative incidences of moderate-to-severe chronic GVHD at 12 and 18 months were 20% and 33%, respectively. The combination of CBD with standard GVHD prophylaxis is a safe and promising strategy to reduce the incidence of acute GVHD. A randomized double-blind controlled study is warranted. (clinicaltrials.gov: NCT01385124).


Leukemia Research | 2014

Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil.

Ron Ram; Corina Herscovici; Dikla Dahan; Moshe Israeli; Juliet Dreyer; Anat Peck; Ofer Shpilberg; Moshe Yeshurun

We hypothesized that in patients with early post allogeneic transplantation toxicities, the omission of the 3rd dose of methotrexate with concomitant starting of MMF would favorably affect complications. We found a higher incidence of grade 2-4 acute GVHD in patients given two doses methotrexate and MMF (n=31) compared to those given three courses of methotrexate (n=70) (p=.004), while grade 3-4 was similar. Other transplantation outcomes, including overall regimen-related-toxicity, were comparable. We conclude that tailoring the GVHD prophylaxis regimen may decrease the early post transplantation complications, however this come at the extent of a higher incidence of non-severe acute GVHD.


American Journal of Hematology | 2014

Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: Randomized controlled trial

Mical Paul; Ron Ram; Eitan Kugler; L. Farbman; Anat Peck; Leonard Leibovici; Meir Lahav; Moshe Yeshurun; Ofer Shpilberg; Corina Herscovici; Ofir Wolach; Gilad Itchaki; Michal Bar-Natan; Liat Vidal; Anat Gafter-Gvili; Pia Raanani

Intravenous (IV) granulocyte colony stimulating factor (G‐CSF) might be safer and more convenient than subcutaneous (SC) administration to hospitalized hemato‐oncological patients receiving chemotherapy. To compare IV vs. SC G‐CSF administration, we conducted a randomized, open‐label trial. We included inpatients receiving chemotherapy for acute myeloid leukemia, acute lymphoblastic leukemia, lymphoma or multiple myeloma, and allogeneic or autologous hematopoietic cell transplantation (HCT). Patients were randomized to 5 mcg/kg single daily dose of IV bolus versus SC filgrastim given for its clinical indications. Patients were crossed‐over to the alternate study arm on the subsequent chemotherapy course. The primary outcomes were time from initiation of filgrastim to recovery of stable neutrophil count of >500 cells/µL and a composite clinical outcome of infection or death assessed for the first course post‐randomization. The study was stopped on the second interim analysis. Of 120 patients randomized, 118 were evaluated in the first treatment course. The mean time to neutropenia resolution was longer with IV G‐CSF [7.9 days, 95% confidence interval (CI) 6.6–9.1] compared with SC G‐CSF (5.4 days, 95% CI 4.6–6.2), log‐rank P = 0.001. Longer neutropenia duration was observed in all patient subgroups, except for patients undergoing autologous HCT. There was no significant difference between groups in the occurrence of infection or death, but more deaths were observed with IV (4/57, 7%) versus SC (1/61, 1.6%) G‐CSF administration, P = 0.196. Similar results were observed when all 158 courses following cross‐over were analyzed. Patients reported similar pain and satisfaction scores in both groups. Bolus IV administration of G‐CSF results in longer neutropenia duration than SC administration, with no difference in clinical or quality‐of‐life measures. Am. J. Hematol. 89:243–248, 2014.


Acta Haematologica | 2016

High-Intensity Induction Chemotherapy Is Feasible for Elderly Patients with Acute Myeloid Leukemia

Adi Shacham-Abulafia; Gilad Itchaki; Moshe Yeshurun; Mical Paul; Anat Peck; Avi Leader; Ofer Shpilberg; Ron Ram; Pia Raanani

Background: The prognosis of elderly patients with acute myeloid leukemia (AML) is poor, and the best treatment is controversial. Since the majority of AML patients are older than 60 years, identification of those who might benefit from intensive treatment is essential. Methods: Data from electronic charts of consecutive AML patients treated in our center were analyzed. Eligibility criteria included newly diagnosed de novo or secondary AML, an age of 60 years or older, and intensive induction treatment. Results: Sixty-two patients were included in the analysis. Forty-six patients (74%) achieved complete remission (CR) after 1-2 intensive induction courses. Twenty of them received consolidation with conventional chemotherapy, 20 proceeded to allogeneic hematopoietic cell transplantation (allo-HCT), and 6 were ineligible for further treatment. The projected overall survival (OS) at 2 and 3 years was 28 and 23%, respectively. A normal karyotype, CR achievement, and allo-HCT were associated with improved OS, while an Eastern Cooperative Oncology Group performance status of 0-1 was borderline associated. The median survival and disease-free survival at 2 years was 18.7 months and 49%, respectively, for patients who underwent allo-HCT in CR1, compared to 12.8 months and 25%, respectively, for those who did not. Conclusion: Based on our data, selected eligible elderly AML patients might benefit from intensive treatment.


Israel Medical Association Journal | 2009

Surveillance of infectious complications in hemato-oncological patients.

Ron Ram; Anat Gafter-Gvili; Pia Raanani; Moshe Yeshurun; Ofer Shpilberg; Juliet Dreyer; Anat Peck; Leonard Leibovici; Mical Paul


Clinical Microbiology and Infection | 2017

Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study

Moshe Yeshurun; Iuliana Vaxman; Liat Shargian; Dafna Yahav; Jihad Bashara; Oren Pasvolski; Ofir Wolach; Meir Lahav; Ronit Gurion; Hila Magen; Liat Vidal; Corina Herscovici; Anat Peck; Maya Moshe; Michal Sela Navon; Elizabeth Naparstek; Pia Raanani; Uri Rozovski


Biology of Blood and Marrow Transplantation | 2014

Cannabidiol – an Innovative Strategy for Graft Versus Host Disease Prevention – an Update of a Phase I/II Study

Moshe Yeshurun; Ofer Shpilberg; Maly Levy-Assaraf; Korina Herscovici; Juliet Dreyer; Anat Peck; Moshe Israeli; Galit Granot; Tsipora Gruenewald; Rafael Mechoulam; Ron Ram


Blood | 2013

Cannabidiol - An Innovative Strategy For Graft Versus Host Disease Prevention

Ofer Shpilberg; Corina Herscovici; Juliet Dreyer; Anat Peck; Maly Levy Assaraf; Tsipora Gruenewald; Raphael Mechoulam; Ron Ram


Biology of Blood and Marrow Transplantation | 2015

Cannabidiol for the Prevention of Graft-Versus-Host-Disease after Allogeneic Stem Cell Transplantation: Results of a Phase I/II Study

Moshe Yeshurun; Ofer Shpilberg; Korina Herscovici; Liat Shargian; Juliet Dreyer; Anat Peck; Moshe Israeli; Maly Levy-Assaraf; Tsipora Gruenewald; Rafael Mechoulam; Pia Raanani; Ron Ram

Collaboration


Dive into the Anat Peck's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mical Paul

Rambam Health Care Campus

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge